| Bioactivity | S2/IAPinh is a conjugate, which consist of an inhibitor for the apoptosis protein inhibitor (IAPinh) and a ligand for sigma 2 SW43. S2/IAPinh exhibits an anti-proliferative and apoptotic-inducing effect through degradation of the cellular inhibitor for apoptosis protein (clAP-1)[1]. |
| Invitro | S2/IAPinh (0-100 μM) 在人胰腺癌细胞系 AsPC-1、HPAC 和 MiaPaCa-2，小鼠胰腺癌细胞系 KP2 和人卵巢癌细胞系 OVCAR3/8 中表现出细胞毒性，IC50 为 4.6 至 12.8 μM，并通过激活 caspase 3 和 caspase 8 诱导 HPAC 和 OVCAR8 中的细胞凋亡 (apoptosis)[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> S2/IAPinh 相关抗体: Cell Viability Assay[1] Cell Line: |
| In Vivo | S2/IAPinh (25 µmol/kg/day，腹腔注射 21 天) 可抑制 KP-2 异种移植 C57BL/6 小鼠和 OVCAR8 异种移植无胸腺裸鼠体内的肿瘤生长并提高小鼠的存活率，无明显毒性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C52H75Cl2FN6O6S |
| Molar Mass | 1002.16 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hagi T, et al., The novel drug candidate S2/IAPinh improves survival in models of pancreatic and ovarian cancer. Sci Rep. 2024 Mar 16;14(1):6373. |